NSE: BIOCON | BSE: 532523

Strong Performer, Getting Expensive

Download real time

410.10 -11.50 (-2.73%)

New 52W High in past week

3.4M NSE+BSE Volume

NSE 19 Nov, 2025 3:31 PM (IST)

54,828.9

Market Cap

Market Leader

1.2

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

20 Nov 2024, 12:00AM

410.10

-2.73%

BIOCON LTD

Accumulate: Biocon Ltd.

Target

Geojit BNP Paribas

Biocon Ltd. has gained 15.15% in the last 1 Month

Biocon Ltd.

12 Nov 2024

410.10

-2.73%

Soft quarter, expect recovery in H2

Buy: Biocon Ltd.

Sharekhan

Revenues stood at Rs. 3,590 crore, up 4% y-o-y and a 5% rise q-o-q. EBITDA reached Rs. 730 crore, down 1% y-o-y but up 24% q-o-q. PAT stood at Rs. 27 crore, a decline of 84% y-o-y and 97% q-o-q.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

31 Oct 2024

410.10

-2.73%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

ICICI Securities Limited increased Sell price target of Biocon Ltd. to 320.0 on 14 Nov, 2025.

Biocon Ltd.

09 Aug 2024

410.10

-2.73%

Result Update:Biocon

Buy: Biocon Ltd.

Axis Direct

We have BUY on the stock

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

05 Aug 2024

410.10

-2.73%

Pick of the Week:05 AUGUST 2024

Buy: Biocon Ltd.

Target

Axis Direct

We recommend BUY With TP OF RS 390 which implies an upside of 10% from the current market price (CMP).

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

28 Jun 2024

410.10

-2.73%

GLP product launch a big opportunity

Buy: Biocon Ltd.

Target

Sharekhan

Biocon recently signed an exclusive licensing and supply agreement with Handok, a South Korean specialty pharma company for commercialization of synthetic liraglutide.

Biocon Ltd. has gained 20.05% in the last 6 Months

Biocon Ltd.

17 May 2024

410.10

-2.73%

Result Update:Biocon

Buy: Biocon Ltd.

Recommendation Target

Axis Direct

We have BUY on the stock

Biocon Ltd. has an average target of 390.50 from 4 brokers.

Biocon Ltd.

12 Feb 2024

410.10

-2.73%

The company's capital allocation is on two fronts - R&D and the acquisition of Viatris.This has resulted in returns ratios falling below ~10% despite growth in the business. A huge looming net debt of $1.2 Bn could lead to further stake dilution in Biocon biologics. Recommendation: HOLD